GLP-1s in Hip and Knee Arthroplasty

What this study is testing ClinicalTrials.gov NCT07755085 ↗

Description as written by the study sponsor.

The number of people living with hip and knee arthritis continues to grow. A large amount of these people are also overweight and diagnosed with obesity. Obesity leads to more stress on hip and knee joints, causing them to wear out sooner. This process is called arthritis. When arthritis gets worse, the joints often need to be replaced due to pain and poor mobility. Very heavy patients often have other health problems that can impair the ability to manage arthritis. Excess weight and health problems can change the way heavy patients recover after surgery, leading to a greater risk of complications. A new type of medicine might be able to improve how obese patients manage their hip and knee pain, as well as improve outcomes after surgery. This type of medicine is called a GLP-1. Investigators will study 2 groups, with one receiving the medicine while the other does not. The goal is to understand how these medications work in the time leading up to surgery and in the early postoperative recovery phase. If these medications help, it may improve the care of high risk obese patients.

Treatments tested

• GLP-1 Receptor Agonists + Behavioral modification Drug

  At least 6 months of preoperative semaglutide and structured behavioural modification

• Behavioral + placebo Behavioral

  Structured behavioural modification - diet, exercise, counselling and placebo medication